Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for ...

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
Drug Delivery Business

Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes

Researchers shared findings today at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. San ...
Nasdaq

Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
AOL

Does Medicare cover Dexcom for glucose monitoring?

People with diabetes can use continuous glucose monitors (CGMs) to make tracking their blood sugar levels easier. Instead of drawing blood multiple times per day, a person continuously wears a sensor ...
Medscape

New Dexcom G7 Feature Cleared as 15-day Sensor Set to Launch

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...